Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Palifermin 6 x 60 μg/kg/day · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Palifermin 6 x 60 μg/kg/day | EXPERIMENTAL | The first 3 consecutive daily doses were administered before the initiation of conditioning therapy (study days -11, -10, and -9); 3 additional consecutive daily doses were administered after administration of radiotherapy, chemotherapy and PBPC transplantation (study days 0, 1, and 2). |
| Palifermin 2 x 180 μg/kg/day | EXPERIMENTAL | The first dose was administered on study day -11, 3 days before the initiation of conditioning therapy, and the second dose was given on day 0 after administration of radiotherapy, chemotherapy and the PBPC infusion |
| Name | Type | Description |
|---|---|---|
| Palifermin 6 x 60 μg/kg/day | DRUG | - |
| Palifermin 2 x 180 μg/kg/day | DRUG | - |
| radiotherapy | RADIATION | - |
| Chemotherapy | DRUG | - |
* Patients diagnosed with Non-Hodgkin's Lymphoma, Hodgkin's Disease, Leukemia and Myeloma. - Eligible for treatment with radiation therapy and chemotherapy followed by blood stem cell support.
Top 20 of 63 competitors
Palifermin 6 x 60 μg/kg/day is an investigational small molecule being studied for use in leukemia. It is also being evaluated in patients with lymphoma and myeloma. The drug is currently in Phase 1 clinical development and has not been approved by the FDA.
Palifermin 6 x 60 μg/kg/day is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in patients with blood cancers.
Palifermin 6 x 60 μg/kg/day is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and no active trials are currently listed for this drug.
Palifermin 6 x 60 μg/kg/day has one completed clinical trial, NCT00070616, titled 'Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support.' This Phase 1 study enrolled 25 participants aged 18 years and older with leukemia, lymphoma, or myeloma.
Palifermin 6 x 60 μg/kg/day is a specific dosing regimen of palifermin, which is the drug's active ingredient. The name indicates a dose of 60 micrograms per kilogram per day, administered six times. The drug is being studied for its effects in patients with blood cancers.